Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Geospatial analyses identify regional hot spots of diffuse gastric cancer in rural Central America.

Dominguez RL, Cherry CB, Estevez-Ordonez D, Mera R, Escamilla V, Pawlita M, Waterboer T, Wilson KT, Peek RM, Tavera G, Williams SM, Gulley ML, Emch M, Morgan DR.

BMC Cancer. 2019 Jun 7;19(1):545. doi: 10.1186/s12885-019-5726-x.

2.

Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements.

He HJ, Stein EV, Konigshofer Y, Forbes T, Tomson FL, Garlick R, Yamada E, Godfrey T, Abe T, Tamura K, Borges M, Goggins M, Elmore S, Gulley ML, Larson JL, Ringel L, Haynes BC, Karlovich C, Williams PM, Garnett A, Ståhlberg A, Filges S, Sorbara L, Young MR, Srivastava S, Cole KD.

J Mol Diagn. 2019 Jul;21(4):658-676. doi: 10.1016/j.jmoldx.2019.03.006. Epub 2019 May 2.

3.

Associations of Epstein-Barr Virus-Positive Gastric Adenocarcinoma with Circulating Mediators of Inflammation and Immune Response.

Camargo MC, Sivins A, Isajevs S, Folkmanis V, Rudzīte D, Gulley ML, Offerhaus GJ, Leja M, Rabkin CS.

Cancers (Basel). 2018 Aug 23;10(9). pii: E284. doi: 10.3390/cancers10090284.

4.

Reporting Results of Molecular Tests: A Retrospective Examination of BRAF Mutation Reporting.

Treece AL, Gulley ML, Vasalos P, Paquette C, Lindeman NI, Jennings LJ, Bartley AN.

Arch Pathol Lab Med. 2017 May;141(5):658-665. doi: 10.5858/arpa.2016-0280-CP. Epub 2017 Mar 13.

PMID:
28447902
5.

Current and Emerging Molecular Tests for Human Papillomavirus-Related Neoplasia in the Genomic Era.

Leal SM Jr, Gulley ML.

J Mol Diagn. 2017 May;19(3):366-377. doi: 10.1016/j.jmoldx.2017.01.006. Epub 2017 Mar 18. Review.

6.

Variation in risk and outcomes of Epstein-Barr virus-associated breast cancer by epidemiologic characteristics and virus detection strategies: an exploratory study.

Glaser SL, Canchola AJ, Keegan TH, Clarke CA, Longacre TA, Gulley ML.

Cancer Causes Control. 2017 Apr;28(4):273-287. doi: 10.1007/s10552-017-0865-3. Epub 2017 Feb 22.

PMID:
28229344
7.

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.

Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA.

J Clin Oncol. 2017 Feb;35(4):446-464. doi: 10.1200/JCO.2016.69.4836. Epub 2016 Nov 14.

PMID:
28129524
8.

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA.

Am J Clin Pathol. 2016 Dec;146(6):647-669. doi: 10.1093/ajcp/aqw206. Epub 2016 Nov 14. Review.

9.

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA.

Arch Pathol Lab Med. 2016 Dec;140(12):1345-1363. Epub 2016 Nov 14.

PMID:
27841667
10.

Karyotypic abnormalities associated with Epstein-Barr virus status in classical Hodgkin lymphoma.

Montgomery ND, Coward WB 4th, Johnson S, Yuan J, Gulley ML, Mathews SP, Kaiser-Rogers K, Rao KW, Sanger WG, Sanmann JN, Fedoriw Y.

Cancer Genet. 2016 Sep;209(9):408-416. doi: 10.1016/j.cancergen.2016.08.006. Epub 2016 Aug 15.

PMID:
27751359
11.

Evaluating Elevated Hemoglobin.

Reeves BN, Gulley ML.

JAMA. 2016 Sep 13;316(10):1114-5. doi: 10.1001/jama.2016.11326. No abstract available.

PMID:
27623471
12.

Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein-Barr virus-related expression patterns.

Treece AL, Duncan DL, Tang W, Elmore S, Morgan DR, Dominguez RL, Speck O, Meyers MO, Gulley ML.

Lab Invest. 2016 Jun;96(6):661-71. doi: 10.1038/labinvest.2016.33. Epub 2016 Mar 7.

13.

FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.

Treece AL, Montgomery ND, Patel NM, Civalier CJ, Dodd LG, Gulley ML, Booker JK, Weck KE.

Cancer Cytopathol. 2016 Jun;124(6):406-14. doi: 10.1002/cncy.21699. Epub 2016 Feb 16.

14.

Identification of Human Papillomavirus Infection in Cancer Tissue by Targeted Next-generation Sequencing.

Montgomery ND, Parker JS, Eberhard DA, Patel NM, Weck KE, Sharpless NE, Hu Z, Hayes DN, Gulley ML.

Appl Immunohistochem Mol Morphol. 2016 Aug;24(7):490-5. doi: 10.1097/PAI.0000000000000215.

15.

Validation and calibration of next-generation sequencing to identify Epstein-Barr virus-positive gastric cancer in The Cancer Genome Atlas.

Camargo MC, Bowlby R, Chu A, Pedamallu CS, Thorsson V, Elmore S, Mungall AJ, Bass AJ, Gulley ML, Rabkin CS.

Gastric Cancer. 2016 Apr;19(2):676-681. doi: 10.1007/s10120-015-0508-x. Epub 2015 Jun 23.

16.

Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC.

Zhao X, Wang A, Walter V, Patel NM, Eberhard DA, Hayward MC, Salazar AH, Jo H, Soloway MG, Wilkerson MD, Parker JS, Yin X, Zhang G, Siegel MB, Rosson GB, Earp HS 3rd, Sharpless NE, Gulley ML, Weck KE, Hayes DN, Moschos SJ.

PLoS One. 2015 Jun 15;10(6):e0129280. doi: 10.1371/journal.pone.0129280. eCollection 2015.

17.

Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma.

Gulley ML.

Exp Mol Med. 2015 Jan 23;47:e134. doi: 10.1038/emm.2014.93. Review.

18.

Three Molecular Subtypes of Gastric Adenocarcinoma Have Distinct Histochemical Features Reflecting Epstein-Barr Virus Infection Status and Neuroendocrine Differentiation.

Speck O, Tang W, Morgan DR, Kuan PF, Meyers MO, Dominguez RL, Martinez E, Gulley ML.

Appl Immunohistochem Mol Morphol. 2015 Oct;23(9):633-45. doi: 10.1097/PAI.0000000000000122.

19.

LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.

Ma SD, Xu X, Plowshay J, Ranheim EA, Burlingham WJ, Jensen JL, Asimakopoulos F, Tang W, Gulley ML, Cesarman E, Gumperz JE, Kenney SC.

J Clin Invest. 2015 Jan;125(1):304-15. doi: 10.1172/JCI76357. Epub 2014 Dec 8.

20.

Molecular oncology testing in resource-limited settings.

Gulley ML, Morgan DR.

J Mol Diagn. 2014 Nov;16(6):601-11. doi: 10.1016/j.jmoldx.2014.07.002. Epub 2014 Sep 19. Review.

21.

Predicting response and survival in chemotherapy-treated triple-negative breast cancer.

Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E.

Br J Cancer. 2014 Oct 14;111(8):1532-41. doi: 10.1038/bjc.2014.444. Epub 2014 Aug 7.

22.

Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.

Pearlstein MV, Zedek DC, Ollila DW, Treece A, Gulley ML, Groben PA, Thomas NE.

J Cutan Pathol. 2014 Sep;41(9):724-32. doi: 10.1111/cup.12364. Epub 2014 Jul 4.

23.

A call to standardize preanalytic data elements for biospecimens.

Robb JA, Gulley ML, Fitzgibbons PL, Kennedy MF, Cosentino LM, Washington K, Dash RC, Branton PA, Jewell SD, Lapham RL.

Arch Pathol Lab Med. 2014 Apr;138(4):526-37. doi: 10.5858/arpa.2013-0250-CP. Epub 2013 Aug 12.

24.

Case-case comparison of smoking and alcohol risk associations with Epstein-Barr virus-positive gastric cancer.

Camargo MC, Koriyama C, Matsuo K, Kim WH, Herrera-Goepfert R, Liao LM; Eurgast-EPIC Group, Yu J, Carrasquilla G, Sung JJ, Alvarado-Cabrero I, Lissowska J, Meneses-Gonzalez F, Yatabe Y, Ding T, Hu N, Taylor PR, Morgan DR, Gulley ML, Torres J, Akiba S, Rabkin CS.

Int J Cancer. 2014 Feb 15;134(4):948-53. doi: 10.1002/ijc.28402. Epub 2013 Aug 28.

25.

Atypical Epstein-Barr viral genomic structure in lymphoma tissue and lymphoid cell lines.

Tang W, Fan H, Schroeder J, Dunphy CH, Bryant RJ, Fedoriw Y, Gulley ML.

Diagn Mol Pathol. 2013 Jun;22(2):91-101. doi: 10.1097/PDM.0b013e318273fb43.

26.

Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis.

Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, Yu J, Sung JJ, Herrera-Goepfert R, Meneses-Gonzalez F, Kijima Y, Natsugoe S, Liao LM, Lissowska J, Kim S, Hu N, Gonzalez CA, Yatabe Y, Koriyama C, Hewitt SM, Akiba S, Gulley ML, Taylor PR, Rabkin CS.

Gut. 2014 Feb;63(2):236-43. doi: 10.1136/gutjnl-2013-304531. Epub 2013 Apr 12.

27.

Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi.

Olson D, Gulley ML, Tang W, Wokocha C, Mechanic O, Hosseinipour M, Gold SH, Nguluwe N, Mwansambo C, Shores C.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):112-8. doi: 10.1016/j.clml.2012.11.003. Epub 2012 Dec 20.

28.

Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile.

Tang W, Morgan DR, Meyers MO, Dominguez RL, Martinez E, Kakudo K, Kuan PF, Banet N, Muallem H, Woodward K, Speck O, Gulley ML.

Infect Agent Cancer. 2012 Aug 28;7(1):21. doi: 10.1186/1750-9378-7-21.

29.

An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.

Ma SD, Yu X, Mertz JE, Gumperz JE, Reinheim E, Zhou Y, Tang W, Burlingham WJ, Gulley ML, Kenney SC.

J Virol. 2012 Aug;86(15):7976-87. doi: 10.1128/JVI.00770-12. Epub 2012 May 23.

30.

Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa.

Ryan JL, Shen YJ, Morgan DR, Thorne LB, Kenney SC, Dominguez RL, Gulley ML.

Dig Dis Sci. 2012 Jul;57(7):1887-98. doi: 10.1007/s10620-012-2116-5. Epub 2012 Mar 13.

31.

Quality assurance of RNA expression profiling in clinical laboratories.

Tang W, Hu Z, Muallem H, Gulley ML.

J Mol Diagn. 2012 Jan;14(1):1-11. doi: 10.1016/j.jmoldx.2011.09.003. Epub 2011 Oct 20. Review.

32.

Systematic bias in genomic classification due to contaminating non-neoplastic tissue in breast tumor samples.

Elloumi F, Hu Z, Li Y, Parker JS, Gulley ML, Amos KD, Troester MA.

BMC Med Genomics. 2011 Jun 30;4:54. doi: 10.1186/1755-8794-4-54.

33.

Epstein-Barr virus microRNAs and lung cancer.

Koshiol J, Gulley ML, Zhao Y, Rubagotti M, Marincola FM, Rotunno M, Tang W, Bergen AW, Bertazzi PA, Roy D, Pesatori AC, Linnoila I, Dittmer D, Goldstein AM, Caporaso NE, McShane LM, Wang E, Landi MT.

Br J Cancer. 2011 Jul 12;105(2):320-6. doi: 10.1038/bjc.2011.221. Epub 2011 Jun 7.

34.

Epstein-Barr virus-specific methylation of human genes in gastric cancer cells.

Ryan JL, Jones RJ, Kenney SC, Rivenbark AG, Tang W, Knight ER, Coleman WB, Gulley ML.

Infect Agent Cancer. 2010 Dec 31;5:27. doi: 10.1186/1750-9378-5-27.

35.

Clinical implementation of RNA signatures for pharmacogenomic decision-making.

Tang W, Hu Z, Muallem H, Gulley ML.

Pharmgenomics Pers Med. 2011;4:95-107. doi: 10.2147/PGPM.S14888. Epub 2011 Sep 8.

36.

A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.

Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, Jankowska-Gan E, Burlingham WJ, Sun X, Gulley ML, Tang W, Gumperz JE, Kenney SC.

J Virol. 2011 Jan;85(1):165-77. doi: 10.1128/JVI.01512-10. Epub 2010 Oct 27.

37.

BRAF mutation testing in colorectal cancer.

Sharma SG, Gulley ML.

Arch Pathol Lab Med. 2010 Aug;134(8):1225-8. doi: 10.1043/2009-0232-RS.1. Review.

PMID:
20670148
38.

Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor 1 alpha expression in nasopharyngeal carcinoma tissue.

Benders AA, Tang W, Middeldorp JM, Greijer AE, Thorne LB, Funkhouser WK, Rathmell WK, Gulley ML.

Head Neck Pathol. 2009 Dec;3(4):276-82. doi: 10.1007/s12105-009-0148-8. Epub 2009 Nov 12.

39.

Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Gulley ML, Tang W.

Clin Microbiol Rev. 2010 Apr;23(2):350-66. doi: 10.1128/CMR.00006-09. Review.

40.

Viral response to chemotherapy in endemic burkitt lymphoma.

Tang W, Harmon P, Gulley ML, Mwansambo C, Kazembe PN, Martinson F, Wokocha C, Kenney SC, Hoffman I, Sigel C, Maygarden S, Hoffman M, Shores C.

Clin Cancer Res. 2010 Apr 1;16(7):2055-64. doi: 10.1158/1078-0432.CCR-09-2424. Epub 2010 Mar 16.

41.

Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.

Gulley ML, Shea TC, Fedoriw Y.

J Mol Diagn. 2010 Jan;12(1):3-16. doi: 10.2353/jmoldx.2010.090054. Epub 2009 Dec 3. Review.

42.

UGT1A1 promoter genotype is not strongly associated with severity of coronary artery disease.

Papez MJ, Civalier CJ, Thorne LB, Gulley ML.

Diagn Mol Pathol. 2009 Dec;18(4):226-31. doi: 10.1097/PDM.0b013e3181a23bbc.

PMID:
19861894
43.

CpG methylation analysis--current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology.

Sepulveda AR, Jones D, Ogino S, Samowitz W, Gulley ML, Edwards R, Levenson V, Pratt VM, Yang B, Nafa K, Yan L, Vitazka P.

J Mol Diagn. 2009 Jul;11(4):266-78. doi: 10.2353/jmoldx.2009.080125. Epub 2009 Jun 18.

44.

Recommended principles and practices for validating clinical molecular pathology tests.

Jennings L, Van Deerlin VM, Gulley ML; College of American Pathologists Molecular Pathology Resource Committee.

Arch Pathol Lab Med. 2009 May;133(5):743-55. doi: 10.1043/1543-2165-133.5.743. Review.

PMID:
19415949
45.

Epstein-Barr virus WZhet DNA can induce lytic replication in epithelial cells in vitro, although WZhet is not detectable in many human tissues in vivo.

Ryan JL, Jones RJ, Elmore SH, Kenney SC, Miller G, Schroeder JC, Gulley ML.

Intervirology. 2009;52(1):8-16. doi: 10.1159/000210833. Epub 2009 Apr 7.

46.

A rational approach to genetic testing for sarcoma.

Gulley ML, Kaiser-Rogers KA.

Diagn Mol Pathol. 2009 Mar;18(1):1-10. doi: 10.1097/PDM.0b013e318181fa05. Review.

PMID:
19214114
47.

High levels of Epstein-Barr virus DNA in latently infected gastric adenocarcinoma.

Ryan JL, Morgan DR, Dominguez RL, Thorne LB, Elmore SH, Mino-Kenudson M, Lauwers GY, Booker JK, Gulley ML.

Lab Invest. 2009 Jan;89(1):80-90. doi: 10.1038/labinvest.2008.103. Epub 2008 Nov 10.

48.

Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival.

Wheless SA, Gulley ML, Raab-Traub N, McNeillie P, Neuringer IP, Ford HJ, Aris RM.

Am J Respir Crit Care Med. 2008 Nov 15;178(10):1060-5. doi: 10.1164/rccm.200804-531OC. Epub 2008 Aug 28.

PMID:
18755927
49.

Multiple pathways for Epstein-Barr virus episome loss from nasopharyngeal carcinoma.

Dittmer DP, Hilscher CJ, Gulley ML, Yang EV, Chen M, Glaser R.

Int J Cancer. 2008 Nov 1;123(9):2105-12. doi: 10.1002/ijc.23685.

50.

Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations.

Glaser SL, Gulley ML, Clarke CA, Keegan TH, Chang ET, Shema SJ, Craig FE, Digiuseppe JA, Dorfman RF, Mann RB, Anton-Culver H, Ambinder RF.

Int J Cancer. 2008 Oct 1;123(7):1499-507. doi: 10.1002/ijc.23741.

Supplemental Content

Loading ...
Support Center